Diagnosis of bile acid diarrhoea by fasting and postprandial measurements of fibroblast growth factor 19

被引:15
|
作者
Borup, Christian [1 ]
Syversen, Charlotte [1 ]
Bouchelouche, Pierre [2 ]
Damgaard, Morten [3 ]
Graff, Jesper [4 ]
Rumessen, Juri Johannes [5 ,6 ]
Munck, Lars Kristian [1 ,7 ]
机构
[1] Koge Hosp, Dept Internal Med, DK-4600 Koge, Denmark
[2] Koge Hosp, Dept Clin Biochem, DK-4600 Koge, Denmark
[3] Koge Hosp, Dept Clin Physiol, DK-4600 Koge, Denmark
[4] Univ Copenhagen, Hvidovre Hosp, Dept Clin Physiol, DK-2650 Hvidovre, Denmark
[5] Gentofte Univ Hosp, Dept Internal Med, Hellerup, Denmark
[6] Gentofte Univ Hosp, Clin Res Unit, Hellerup, Denmark
[7] Univ Copenhagen, Fac Hlth & Human Sci, Copenhagen, Denmark
关键词
bile acids and salts; diarrhoea; fibroblast growth factors; malabsorption syndromes; IRRITABLE-BOWEL-SYNDROME; MALABSORPTION; PREVALENCE;
D O I
10.1097/MEG.0000000000000476
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background A deficiency in the ileal hormone fibroblast growth factor 19 (FGF19) has been described in patients with bile acid diarrhoea (BAD), but fasting FGF19 levels have insufficient diagnostic power. We assess whether single postprandial sampling of FGF19 has greater discriminative value than fasting FGF19 for detection of BAD and we evaluate the reproducibility of fasting FGF19. Materials and methods Twenty-six patients consecutively referred to Se-75 homocholic acid retention test (SeHCAT) were included. Serum FGF19 was measured after an overnight fast and again 1h postprandially and again in the fasting state 1 week later. Results Nine of 26 patients had SeHCAT less than 10% and fasting FGF19 was lower [median 62 pg/ml, interquartile range (IQR): 47-67] than in the 17 diarrhoea controls with SeHCAT at least 10% (median 103 pg/ml, IQR: 77-135, P = 0.006). Postprandial FGF19 in BAD patients (61 pg/ml, IQR: 48-69) was similar to fasting values (P = 0.59) and increased insignificantly in diarrhoea controls (137 pg/ml, IQR: 88-182; P = 0.25). The difference in postprandial FGF19 between patients with BAD and diarrhoea controls was highly significant (P < 0.001). Conclusion The difference in serum FGF19 between groups of patients with BAD and diarrhoea controls is amplified postprandially. Within each group, the difference between fasting and postprandial FGF19 was not statistically significant. Further investigations are warranted on stimulated FGF19 response to elucidate its role in BAD. Copyright (C) 2015 Wolters Kluwer Health, Inc. All rights reserved.
引用
收藏
页码:1399 / 1402
页数:4
相关论文
共 50 条
  • [1] EVALUATION OF FIBROBLAST GROWTH FACTOR 19 IN THE DIAGNOSIS OF BILE ACID DIARRHOEA
    Pattni, S.
    Dew, T.
    Srinivas, M.
    Basumani, P.
    Bardhan, K. D.
    Walters, J. R. F.
    GUT, 2011, 60 : A88 - A88
  • [2] Commentary: fibroblast growth factor 19 in patients with bile acid diarrhoea
    Camilleri, M.
    Acosta, A.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2013, 38 (10) : 1320 - 1321
  • [3] Evaluation of Fibroblast Growth Factor 19 in the Diagnosis of Bile Acid Diarrhea
    Pattni, Sanjeev S.
    Dew, Tracy
    Srinivas, Melpakkam
    Basumani, Pandurangan
    Bardhan, Karna D.
    Walters, Julian R.
    GASTROENTEROLOGY, 2011, 140 (05) : S284 - S284
  • [4] Downregulation of Serum and Distal Ileum Fibroblast Growth Factor19 in Bile Acid Diarrhoea Patients
    Chunxia Chang
    Jingjing Jiang
    Rui Sun
    Shenggen Wang
    Hong Chen
    Digestive Diseases and Sciences, 2022, 67 : 872 - 879
  • [5] A PROSPECTIVE STUDY OF FIBROBLAST GROWTH FACTOR 19 IN PATIENTS WITH CHRONIC DIARRHOEA AND POSSIBLE BILE ACID MALABSORPTION
    Pattni, S.
    Dew, T.
    Walters, J. R. F.
    GUT, 2010, 59 : A48 - A48
  • [6] Downregulation of Serum and Distal Ileum Fibroblast Growth Factor19 in Bile Acid Diarrhoea Patients
    Chang, Chunxia
    Jiang, Jingjing
    Sun, Rui
    Wang, Shenggen
    Chen, Hong
    DIGESTIVE DISEASES AND SCIENCES, 2022, 67 (03) : 872 - 879
  • [7] Chenodeoxycholic acid stimulated fibroblast growth factor 19 response - a potential biochemical test for bile acid diarrhoea.
    Borup, C.
    Wildt, S.
    Rumessen, J. J.
    Bouchelouche, P. N.
    Graff, J.
    Damgaard, M.
    McQuitty, C.
    Rainteau, D.
    Munck, L. K.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2017, 45 (11) : 1433 - 1442
  • [8] STIMULATED EXPRESSION OF ILEAL FIBROBLAST GROWTH FACTOR 19 BY BILE ACIDS IS IMPAIRED IN PATIENTS WITH PRIMARY AND SECONDARY BILE ACID DIARRHOEA
    Nolan, J. D.
    Appleby, R. N.
    Madhan, G. K.
    Johnston, I. M.
    Sarah, K.
    Zhang, J. H.
    Walters, J.
    GUT, 2015, 64 : A19 - A19
  • [9] Fibroblast growth factor 19 in patients with bile acid diarrhoea: a prospective comparison of FGF19 serum assay and SeHCAT retention
    Pattni, S. S.
    Brydon, W. G.
    Dew, T.
    Johnston, I. M.
    Nolan, J. D.
    Srinivas, M.
    Basumani, P.
    Bardhan, K. D.
    Walters, J. R. F.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2013, 38 (08) : 967 - 976
  • [10] Effects of conventional and a novel colonic-release bile acid sequestrant, A3384, on fibroblast growth factor 19 and bile acid metabolism in healthy volunteers and patients with bile acid diarrhoea
    Appleby, R. N.
    Bajor, A.
    Gillberg, P-G
    Graffner, H.
    Simren, M.
    Ung, K. A.
    Walters, J. R. F.
    UNITED EUROPEAN GASTROENTEROLOGY JOURNAL, 2017, 5 (03) : 380 - 388